Funding agencies: This research was supported by the Canadian Institutes of Health Research (T 0602145.02), and an operating grant from genome Quebec (Complications Associated with obesity; CAO). Rémi Rabasa-Lhoret holds a scholarship from FRSQ (Fonds de Recherche en Santé du Québec and is the recipient of the J-A DeSéve chair in clinical research). Siham Yasari is currently employed by the Canadian Institutes of Health Research and she declares no conflict of interests. Vincenzo Di Marzo and Fabiana Piscitelli are recipients of an NIH grant (DA-009789).
Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study
Article first published online: 19 OCT 2013
© 2013 The Obesity Society
Volume 22, Issue 1, pages 211–216, January 2014
How to Cite
Abdulnour, J., Yasari, S., Rabasa-Lhoret, R., Faraj, May., Petrosino, S., Piscitelli, F., Prud' homme, D. and Di Marzo, V. (2014), Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study. Obesity, 22: 211–216. doi: 10.1002/oby.20498
Disclosure: The authors declare no conflict of interest.
Author Contributions: Joseph Abdulnour, Siham Yasari, Remi Rabasa-Lhoret, Vincenzo Di Marzo and Denis Prud'homme played a role in the conception/design as well as the acquisition of data. Stefania Petrosino and Fabiana Piscitelli carried out the endocannabinoid measurements. All authors were involved in writing and interpreting the paper and gave final approval of the submitted and published versions.
- Issue published online: 11 JAN 2014
- Article first published online: 19 OCT 2013
- Accepted manuscript online: 24 APR 2013 02:54PM EST
- Manuscript Accepted: 28 MAR 2013
- Manuscript Received:
To measure the circulating levels of endocannabinoids and related molecules at fasting, after acute hyperinsulinemia and after weight loss in insulin sensitive vs. insulin resistant obese postmenopausal women.
Design and Methods
The sample consisted of 30 obese postmenopausal women (age: 58.9 ± 5.2 yrs; BMI: 32.9 ± 3.6 kg/m2). Subjects underwent a 3-hour hyperinsulinaemic-euglycaemic clamp (HEC) (glucose disposal rate (M-value): 10.7 ± 3.3 mg min−1 kg−1 FFM) and 6-month weight loss intervention. Participants were classified as insulin sensitive obese (ISO) or insulin resistant obese (IRO) based on a predefined cutoff. Plasma levels of the endocannabinoids, anandamide (AEA), 2-arachidonoylglycerol (2-AG), and of the AEA-related compounds, palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), were measured by liquid chromatography-mass spectrometry.
IRO presented higher levels of 2-AG (P < 0.05) independently of the HEC and weight loss, whereas the HEC had an independent inhibitory effect on AEA, PEA, and OEA levels (P < 0.05) in both groups. Furthermore, there was an independent stimulatory effect of weight loss only on PEA levels in both groups (P < 0.05).
This study is the first to show that higher circulating levels of the endocannabinoid 2-AG are found in IRO compared to ISO postmenopausal women, and that weight loss is associated with an increase in PEA, a PPAR-α ligand.